Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
2007 (English)In: European Journal of Health Economics, ISSN 1618-7598, E-ISSN 1618-7601, Vol. 8, no 4, 313-323 p.Article in journal (Refereed) Published
A model was developed to estimate costs and clinical effectiveness of fondaparinux compared with enoxaparin after hip fracture surgery in Sweden. Outcomes and costs of venous thromboembolism (VTE)-related care from a health care perspective were incorporated, with symptomatic deep-vein thrombosis and pulmonary embolism, recurrent VTE, post-thrombotic syndrome, major haemorrhage and all-cause death being included. Event probabilities were derived from fondaparinux clinical trial data and published data. VTE-related resource use and associated costs as well as costs of prophylaxis were based on local Swedish data. Extended prophylaxis with fondaparinux could avoid an additional 28 symptomatic VTE per 1,000 patients compared with extended prophylaxis with enoxaparin in hip fracture surgery patients. Although the prophylaxis costs were higher in the fondaparinux group, these were offset by the lower costs associated with treating fewer VTE, which thus indicates that extended fondaparinux prophylaxis is the dominant alternative when compared with enoxaparin in hip fracture surgery.
Place, publisher, year, edition, pages
2007. Vol. 8, no 4, 313-323 p.
Venous thrombosis, Surgery, Deep vein thrombosis, Pulmonary embolism, Cost-effectiveness
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-10979DOI: 10.1007/s10198-006-0017-2ISI: 000253955200003PubMedID: 17225129OAI: oai:DiVA.org:uu-10979DiVA: diva2:38747